for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CSL Limited

CSL.AX

Latest Trade

270.58AUD

Change

0.18(+0.07%)

Volume

421,438

Today's Range

268.52

 - 

274.62

52 Week Range

242.00

 - 

319.78

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Pricing

Previous Close
270.40
Open
273.16
Volume
421,438
3M AVG Volume
16.73
Today's High
274.62
Today's Low
268.52
52 Week High
319.78
52 Week Low
242.00
Shares Out (MIL)
455.13
Market Cap (MIL)
129,453.60
Forward P/E
40.51
Dividend (Yield %)
1.09

Next Event

Half Year 2022 CSL Ltd Earnings Release

Latest Developments

More

CSL Says Completed A$6.3 Bln Institutional Placement

CSL says Vifor acquisition is strategic, not a synergy deal

CSL Announces Cash Offer At US$179.25 Per Share To Acquire Vifor Pharma

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CSL Limited

CSL Limited is an Australia-based biotechnology company. The Company is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. It offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The Company operates through two segments: CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Its products include PRIVIGEN, IDELVION and AFSTYLA.

Industry

Biotechnology & Drugs

Contact Info

45 Poplar Road,, Parkville

MELBOURNE, VIC

3052

Australia

+61.3.93891911

https://www.csl.com/

Executive Leadership

Brian Anthony McNamee

Non-Executive Independent Chairman of the Board

Paul Perreault

Chief Executive Officer, Managing Director, Executive Director

Joy Linton

Chief Financial Officer

Paul F. McKenzie

Chief Operating Officer

Elizabeth Walker

Chief Human Resource Officer, Executive Vice President

Key Stats

2.23 mean rating - 13 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

8.5K

2020

9.2K

2021

10.3K

2022(E)

10.7K
EPS (USD)

2019

4.226

2020

4.615

2021

5.210

2022(E)

4.859
Price To Earnings (TTM)
37.30
Price To Sales (TTM)
9.02
Price To Book (MRQ)
10.55
Price To Cash Flow (TTM)
32.39
Total Debt To Equity (MRQ)
69.28
LT Debt To Equity (MRQ)
63.63
Return on Investment (TTM)
16.65
Return on Equity (TTM)
14.06

Latest News

Latest News

CSL, energy stocks drag Australia shares lower; tech rally limits losses

Australian shares slipped on Thursday, hit by health firm CSL Ltd and energy stocks, though gains in tech stocks tracking their U.S. peers helped limit losses.

Australia's CSL to buy Swiss drugmaker Vifor for $11.7 billion

Australian biopharmaceutical giant CSL Ltd said it would buy Swiss drugmaker Vifor Pharma AG for $11.7 billion, as it aims to diversify beyond its blood plasma collection business that took a hit from COVID-19 curbs.

Australia's CSL enters trading halt ahead of deal for drugmaker Vifor

Australian biopharmaceutical giant CSL Ltd on Tuesday applied for a trading halt in its shares ahead of an expected deal to buy Swiss drugmaker Vifor Pharma AG .

Vifor Pharma shares jump 15% as takeover talks with CSL confirmed

Vifor Pharma's shares surged more than 15% in early trading on Monday after the Swiss drugmaker and Australia's CSL both confirmed they were talking about a potential merger.

Australia's CSL in talks to buy Swiss drugmaker Vifor

Australian biopharmaceutical giant CSL Ltd on Monday confirmed it was in talks to buy Swiss drugmaker Vifor Pharma Ltd.

Australia's CSL in exclusive talks for $7 billion buyout of Swiss Vifor Pharma - report

Australian biopharmaceutical giant CSL Ltd is in exclusive talks to buy Swiss drugmaker Vifor Pharma in a A$10 billion ($7 billion) deal, Australian media reported, sending the Swiss drugmaker's shares up by a fifth.

Australia's CSL reaffirms commitment to making AstraZeneca COVID vaccine

Australian biotech CSL said on Thursday it was committed to its agreement for the production of about 50 million doses of AstraZeneca's COVID-19 vaccine into 2022.

Australia's CSL reiterates manufacturing commitment with AstraZeneca COVID-19 vaccine

Australian biotech CSL said on Thursday it was committed to its manufacturing agreement of about 50 million doses with AstraZeneca's COVID-19 vaccine into 2022.

Seqirus says it can supply 60 million doses of influenza vaccines for U.S. flu season

Vaccine maker Seqirus, a part of Australia-based biotech company CSL Ltd, said on Tuesday it has started shipping its influenza vaccines to the United States and can supply about 60 million doses of its shots for the upcoming flu season.

Seqirus says can supply 60 mln doses of influenza vaccines for U.S. flu season

Vaccine maker Seqirus, a part of Australia-based biotech company CSL ltd, said on Tuesday it has started shipping its influenza vaccines to the United States and can supply about 60 million doses of its shots for the upcoming flu season.

Australia's CSL unable to simultaneously make Novavax, AstraZeneca vaccines

CSL Ltd said on Thursday it does not have the capacity to simultaneously produce AstraZeneca and Novavax Inc's COVID-19 vaccines after a local report said the U.S.-based firm was looking for an Australian manufacturing partner.

BRIEF-CSL Says Does Not Have Capacity To Simultaneously Make AstraZeneca And Novavax COVID-19 Vaccines

* AT THIS TIME CSL DOES NOT HAVE CAPACITY TO SIMULTANEOUSLY MAKE BOTH ASTRAZENECA AND NOVAVAX COVID-19 VACCINES- CSL SPOKESWOMAN

Australia doubles Pfizer vaccine order as Astra clotting worries upend rollout

Australia has doubled its order of the Pfizer Inc COVID-19 vaccine, Prime Minister Scott Morrison said on Friday, as the country raced to overhaul its inoculation plan over concerns about the risks of blood clots with the AstraZeneca Plc vaccine.

Australia's COVID-19 vaccine roll-out misses targets

Australia has fallen far behind its target for COVID-19 vaccinations, figures showed on Wednesday, with only about 670,000 people inoculated against an initial target of 4 million by end-March.

UPDATE 1-Australia's CSL half-year profit jumps 45% on strong blood plasma product demand

Australian biotech CSL Ltd on Thursday reported a 45% rise in half-year profit, boosted by higher demand for its vaccines and blood plasma products.

Australia's CSL reports 45% jump in half-year profit

Australian biotech CSL Ltd on Thursday reported a 45% rise in half-year profit, boosted by higher demand for its vaccines and blood plasma products.

Australia halts local COVID-19 vaccine development due to false HIV positives

Australia cancelled the production of a locally made vaccine against COVID-19 after trials showed it could interfere with HIV diagnosis, with the government instead securing additional doses of rival vaccines.

Australia's CSL to not go to phase 2 trials for COVID-19 vaccine

Australia's CSL Ltd said on Friday it would not take its COVID-19 vaccine candidate, being developed with the University of Queensland, to phase 2 and 3 clinical trials after trial participants returned false positive HIV test results.

BRIEF-CSL Says Will Not Progress UQ-CSL V451 COVID-19 Vaccine Candidate To Phase 2/3 Clinical Trials

* CSL WILL NOT PROGRESS VACCINE CANDIDATE TO PHASE 2/3 CLINICAL TRIALS

Australia to spend $726 mln underwriting country's biggest vaccine plant

Australia will spend A$1 billion ($726.3 million) underwriting construction of a vaccine manufacturing plant under a deal with a unit of biomedical giant CSL Ltd, guaranteeing supply of flu shots and antivenins, the federal government said on Monday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up